" class="no-js "lang="en-US"> CimCure - Medtech Alert
Tuesday, August 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
CimCure | Pharmtech Focus

CimCure

About CimCure

CimCure

CimCure is a new generation company founded by its CSO in 2015, as a spin-off company of Amsterdam UMC. CimCure focuses on design and development of a novel class of active cancer vaccines.

Related Story

Diseases

 Covalab

Covalab, Cimcure and Partners Receive €1.06M EUREKA Eurostars Grant to Develop New Combination Therapy for Glioblastoma

September 21 2022

Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and […]

COVID-19

 Cancer Vaccine Biotech CimCure Raises € 5 Million in Seed Round Investment Led by Positron Ventures | Pharmtech Focus

Cancer Vaccine Biotech CimCure Raises € 5 Million in Seed Round Investment Led by Positron Ventures

June 7 2022

CimCure, a biotech spin-off of Amsterdam UMC, focusing on the development of a novel vaccine-based […]